Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.71 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | NAAA | Q02083 | 1/20 | 0.57 |
| ▸ | PPID | Q08752 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3420583 | 0.98 | EPHX2 (0.69) | EPHX2EPHX1ALDH1A1HTTKEAP1 | |
| SCHEMBL3403502 | 0.98 | EPHX2 (0.69) | EPHX2EPHX1ALDH1A1HTTKEAP1 | |
| SCHEMBL11260446 | 0.98 | EPHX2 (0.69) | EPHX2EPHX1ALDH1A1HTTKEAP1 | |
| SCHEMBL11035774 | 0.98 | EPHX2 (0.69) | EPHX2EPHX1ALDH1A1HTTKEAP1 | |
| SCHEMBL3421197 | 0.95 | EPHX2 (0.73) | EPHX2EPHX1ALDH1A1HTTKEAP1 | |
| Urea SCHEMBL717178 | 0.90 | EPHX2 (0.67) | EPHX2EPHX1ALDH1A1HTTKEAP1 | |
| SCHEMBL11035964 | 0.90 | EPHX1 (0.68) | EPHX2EPHX1ALDH1A1HTT | |
| SCHEMBL11034979 | 0.90 | EPHX1 (0.68) | EPHX2EPHX1ALDH1A1HTT | |
| SCHEMBL6438376 | 0.90 | EPHX2 (0.80) | EPHX2EPHX1KEAP1NFE2L2SMN1; SMN2 | |
| SCHEMBL6436358 | 0.90 | EPHX2 (0.80) | EPHX2EPHX1KEAP1NFE2L2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393958-B2 | Triamide-substituted heterobicyclic compounds | PFIZER, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7368573-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2008-05-06 | — | — | US | disclosed |
| EP-1799648-A1 | 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINE COMPOUNDS | Pfizer Products Inc. (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2007-04-26 | — | — | US | disclosed |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | BERTINATO PETER | 2006-10-05 | — | — | US | disclosed |
| WO-2006033002-A1 | 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | APOB, MTPN, CTRB1 | EPHX2 1418/4885EPHX1 1290/4885ALDH1A1 3299/4885 |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | APOB, MTPN, CTRB1 | EPHX2 1418/4885EPHX1 1290/4885ALDH1A1 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.